Skip to content
Open access · CC-BY via OpenAlex

IGF-1R Inhibitor Ameliorates Neuroinflammation in an Alzheimer’s Disease Transgenic Mouse Model

Mona Sohrabi, Angela Marie Floden, Gunjan Dhawan Manocha, Marilyn G. Klug, Colin Kelly Combs

Frontiers in Cellular Neuroscience · 2020 · ▲ 49 citations

Abstract

Aging is a major risk factor for Alzheimer’s disease (AD). Insulin like growth factor-1 receptor (IGF-1R) regulates general aging and lifespan. However, the contribution of IGF-1 to age-related AD pathology and progression is highly controversial. Based on our previous work, AβPP/PS1 double transgenic mice, which express human mutant amyloid precursor protein (APP) and presenilin-1 (PS-1), demonstrated a decrease in brain IGF-1 levels when they were crossed with IGF-1 deficient Ames dwarf mice (df/df). Subsequently, a reduction in gliosis, amyloid-β (Aβ) plaque deposition, and Aβ1-40/42 concentrations were observed in this mouse model. This supported the hypothesis that IGF-1 may contribute to progression of disease. To assess the role of IGF-1 in AD, 9-10-month-old male littermate control wild type and AβPP/PS1 mice were randomly divided into 2 treatment groups including control vehicle (DMSO) and picropodophyllin (PPP), a selective, competitive, and reversible IGF-1R inhibitor. The brain penetrant inhibitor was given ip. at 1mg/kg/day. Mice were sacrificed after 7 days of daily injection and the brains, spleens, and livers were collected to quantify histologic and biochemical changes. The PPP-treated AβPP/PS1 mice demonstrated attenuated insoluble Aβ1-40/42 and pro-inflammatory cytokine levels in the temporal cortex including eotaxin, TNF-, IL-1, and IL-1. Additionally, an attenuation in microgliosis and protein p-tyrosine levels were observed due to drug treatment in the hippocampus. Our data suggests IGF-1R signaling is associated with disease progression in this mouse model. More importantly, modulation of the brain IGF-1R signaling pathway, even at mid-life, was enough to attenuate aspects of disease phenotype. This suggests that small molecule therapy targeting the IGF-1R pathway may be viable for late stage disease treatment.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3389/fncel.2020.00200
Canonical
link ↗
Fetched
2026-10-22 MST

Cite this

APA
Sohrabi, M., Floden, A.M., Manocha, G.D., Klug, M.G., &amp; Combs, C.K. (2020). IGF-1R Inhibitor Ameliorates Neuroinflammation in an Alzheimer’s Disease Transgenic Mouse Model. <em>Frontiers in Cellular Neuroscience</em>. https://doi.org/10.3389/fncel.2020.00200
Vancouver
Sohrabi M, Floden AM, Manocha GD, Klug MG, Combs CK. IGF-1R Inhibitor Ameliorates Neuroinflammation in an Alzheimer’s Disease Transgenic Mouse Model. Frontiers in Cellular Neuroscience. 2020. doi:10.3389/fncel.2020.00200.
BibTeX
@article{mona2020IGFRIn, title = {IGF-1R Inhibitor Ameliorates Neuroinflammation in an Alzheimer’s Disease Transgenic Mouse Model}, author = {Mona Sohrabi and Angela Marie Floden and Gunjan Dhawan Manocha and Marilyn G. Klug and Colin Kelly Combs}, journal = {Frontiers in Cellular Neuroscience}, year = {2020}, doi = {10.3389/fncel.2020.00200}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings